The Lassa Fever (Lassa Hemorrhagic Fever) drugs in development market research report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lassa Fever (Lassa Hemorrhagic Fever). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Lassa Fever (Lassa Hemorrhagic Fever) by 24 companies/universities/institutes. The top development phase for Lassa Fever (Lassa Hemorrhagic Fever) is preclinical with 16 drugs in that stage. The Lassa Fever (Lassa Hemorrhagic Fever) pipeline has 21 drugs in development by companies and six by universities/ institutes. Some of the companies in the Lassa Fever (Lassa Hemorrhagic Fever) pipeline products market are: Helix Biogen Institute, DIOSynVax and SK Bioscience.
The key targets in the Lassa Fever (Lassa Hemorrhagic Fever) pipeline products market include RNA Directed RNA Polymerase, Toll-Llike Receptor 7, and Ebola virus Matrix Protein VP40.
The key mechanisms of action in the Lassa Fever (Lassa Hemorrhagic Fever) pipeline product include RNA Directed RNA Polymerase Inhibitor with one drug in Phase II. The Lassa Fever (Lassa Hemorrhagic Fever) pipeline products include three routes of administration with the top ROA being Intramuscular and eight key molecule types in the Lassa Fever (Lassa Hemorrhagic Fever) pipeline products market including Recombinant Vector Vaccine, and Subunit Vaccine.
Lassa Fever (Lassa Hemorrhagic Fever) overview
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes, and bleeding. The antiviral drug ribavirin seems to be an effective treatment for Lassa fever if given early on in the course of clinical illness.
For a complete picture of Lassa Fever (Lassa Hemorrhagic Fever)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
